This is based on the observation of the association between CD200 expression and other CSC markers, such as CD44+/CD24− in breast cancer, CD44+ in prostate cancer, CD133 in CRC, BMI1 and Shh in HNSCC [57, 92, 93]. The gene discussed is CD44; the disease is prostate carcinoma.